The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|5|701-710

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.5, 2015-06, pp. : 701-710

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

By Dillman R.  

Clinical and Experimental Medicine, Vol. 6, Iss. 1, 2006-03 ,pp. : 1-12

Springer Publishing Company

Access to resources Recommend Favorite

Immunotherapy with the trifunctional anti‐CD20 x anti‐CD3 antibody FBTA05 (Lymphomun) in paediatric high‐risk patients with recurrent CD20‐positive B cell malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 90-102

John Wiley & Sons Inc

Access to resources Recommend Favorite

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite

Prevention of acute graft‐versus‐host disease by humanized anti‐CD26 monoclonal antibody

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 162, Iss. 2, 2013-07 ,pp. : 263-277

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antitumor activity of an anti‐CD98 antibody

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 3, 2015-08 ,pp. : 710-720

John Wiley & Sons Inc

Access to resources Recommend Favorite